Researchers have found that infliximab, a drug initially approved for autoimmune diseases, may be an effective treatment for Kawasaki disease, particularly in cases resistant to standard therapy. The European Commission has granted it orphan drug designation, following a similar approval from the U.S. Food and Drug Administration (FDA). This designation is crucial as Kawasaki disease primarily affects children under five and can lead to serious heart complications if not treated promptly.

For parents and caregivers, this development is significant because Kawasaki disease is the leading cause of acquired heart disease in children in developed countries. Current treatments, like high-dose intravenous immunoglobulin (IVIG), fail in 10 to 20% of cases, leaving many children at risk for severe heart issues. Infliximab has shown promise in clinical trials, reducing fever duration and hospital stays, which could lead to better health outcomes for affected children.

The evidence comes from the KIDCARE trial, a large, randomized study involving 103 children across 30 hospitals in the U.S. This trial demonstrated that infliximab is safe and effective for children who do not respond to IVIG. While this research is robust, it is important to note that infliximab is still in the process of being officially approved for this specific use in Kawasaki disease.

If you are a parent of a child with Kawasaki disease or are concerned about the condition, it’s wise to stay informed about new treatments and consult with healthcare providers about the latest options available.

Source: globenewswire.com